Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Alfredo Chetta, Nicola Facciolongo, Cosimo Franco, Laura Franzini, Alessio Piraino & Carmelina Rossi. (2022) Impulse Oscillometry, Small Airways Disease, and Extra-Fine Formulations in Asthma and Chronic Obstructive Pulmonary Disease: Windows for New Opportunities. Therapeutics and Clinical Risk Management 18, pages 965-979.
Read now
Read now
Anees ur Rehman, Mohamed Azmi Ahmad Hassali, Sohail Ayaz Muhammad, Shahid Shah, Sameen Abbas, Irfhan Ali Bin Hyder Ali & Ahmad Salman. (2020) The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. Expert Review of Pharmacoeconomics & Outcomes Research 20:6, pages 661-672.
Read now
Read now
Lirong Liang, Yunxiao Shang, Wuxiang Xie, Julie Shi, Zhaohui Tong & Mohammad S Jalali. (2020) Trends in Hospitalization Expenditures for Acute Exacerbations of COPD in Beijing from 2009 to 2017. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1165-1175.
Read now
Read now
Eirini Stafyla, Mary Geitona, Theodora Kerenidi, Athina Economou, Zoe Daniil & Konstantinos I Gourgoulianis. (2018) The annual direct costs of stable COPD in Greece. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 309-315.
Read now
Read now
Eirini Stafyla, Ourania S Kotsiou, Konstantina Deskata & Konstantinos I Gourgoulianis. (2018) Missed diagnosis and overtreatment of COPD among smoking primary care population in Central Greece: old problems persist. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 487-498.
Read now
Read now
Articles from other publishers (16)
Roberto W. Dal Negro, Matteo Poletti & Massimo Pistolesi. (2021) Standard spirometry to assess emphysema in patients with chronic obstructive pulmonary disease: the Emphysema Severity Index (ESI). Multidisciplinary Respiratory Medicine 16.
Crossref
Crossref
Roberto W. Dal Negro, Mauro Carone, Giuseppina Cuttitta, Luca Gallelli, Massimo Pistolesi, Salvatore Privitera, Piero Ceriana, Pietro Pirina, Bruno Balbi, Carlo Vancheri, Franca M. Gallo, Alfredo Chetta, Paola Turco & On behalf of the CLIMA Study Group*. (2021) Prevalence and clinical features of most frequent phenotypes in the Italian COPD population: the CLIMA Study. Multidisciplinary Respiratory Medicine 16.
Crossref
Crossref
Alexandru Corlateanu, Alexandra Plahotniuc, Olga Corlateanu, Victor Botnaru, Andras Bikov, Alexander G. Mathioudakis, Serghei Covantev & Nikolaos Siafakas. (2021) Multidimensional indices in the assessment of chronic obstructive pulmonary disease. Respiratory Medicine 185, pages 106519.
Crossref
Crossref
Jaromir Zatloukal, Kristian Brat, Katerina Neumannova, Eva Volakova, Karel Hejduk, Eva Kocova, Ondrej Kudela, Michal Kopecky, Marek Plutinsky & Vladimir Koblizek. (2020) Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society. Biomedical Papers 164:4, pages 325-356.
Crossref
Crossref
Suhaj Abdulsalim, Mazhuvancherry Kesavan Unnikrishnan, Mohan K. Manu, Saud Alsahali, Alian A. Alrasheedy, Antony P. Martin, Brian Godman & Abubakr A. Alfadl. (2019) Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India. PharmacoEconomics - Open 4:2, pages 331-342.
Crossref
Crossref
Y.-E. Claessens, X. Delecour & N. Beau. (2020) Polmonite acuta comunitaria dell’adulto al Pronto Soccorso. EMC - Urgenze 24:1, pages 1-15.
Crossref
Crossref
Anees ur Rehman, Mohamed Azmi Ahmad Hassali, Sohail Ayaz Muhammad, Sabariah Noor Harun, Shahid Shah & Sameen Abbas. (2019) The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. The European Journal of Health Economics 21:2, pages 181-194.
Crossref
Crossref
Angelo G. Corsico, Fulvio Braido, Marco Contoli, Fabiano Di Marco, Paola Rogliani, Carla Scognamillo, Irene Olivi, Pierachille Santus, Nicola Scichilone & Carlo Lazzaro. (2019) Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up. Respiratory Medicine 153, pages 68-75.
Crossref
Crossref
Roberto Dal Negro. (2019) COPD: The Annual Cost-Of-Illness during the Last Two Decades in Italy, and Its Mortality Predictivity Power. Healthcare 7:1, pages 35.
Crossref
Crossref
Andrea Aiello, Daniela Ritrovato & Claudia Pitotti. (2018) Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2018, pages 228424031880480.
Crossref
Crossref
Roberto W. Dal Negro & Claudio F. Donner. 2018. Textbook of Pulmonary Rehabilitation. Textbook of Pulmonary Rehabilitation
273
282
.
R.W. Dal Negro & B.R. Celli. (2017) Patient Related Outcomes-BODE (PRO-BODE): A composite index incorporating health utilization resources predicts mortality and economic cost of COPD in real life. Respiratory Medicine 131, pages 175-178.
Crossref
Crossref
Roberto W. Dal Negro & Bartolome R. Celli. (2016) The BODECOST Index (BCI): a composite index for assessing the impact of COPD in real life. Multidisciplinary Respiratory Medicine 11:1.
Crossref
Crossref
Sergio Iannazzo, Chiara Distante & Angelo Guido Corsico. (2016) Costs of Tiotropium Bromide Delivered via the Respimat® Inhaler in COPD Patients in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 3:2, pages GRHTA.5000220.
Crossref
Crossref
R.W. Dal Negro, M. Visconti & P. Turco. (2015) Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial. Pulmonary Pharmacology & Therapeutics 33, pages 47-51.
Crossref
Crossref
. (2015) Guideline-based treatment reduces COPD-related costs. PharmacoEconomics & Outcomes News 724:1, pages 10-10.
Crossref
Crossref